Last updated 2026-07-27
- Went public on NASDAQ (CGEN), Aug 2000
- Raised $35.4M Series B led by Apax, Jul 2000
- Public offering on TASE, Jan 2002
Total raised
$40.3M
Stage
Public
Founded
1993
Headcount
110
HQ
Holon, Israel
Sector
Health Tech & Life Sciences
About
Compugen is a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery. The company has been at the forefront of decoding cancer biology with its AI-powered predictive computational discovery platform, Unigen™. Unigen™ combines deep scientific knowledge, AI/ML predictive algorithms, and a cloud-based, technology-agnostic platform integrating various biological data. The outcomes from preclinical and clinical trials enrich its proprietary knowledgebase to discover additional novel drug targets and further understand complex biology. To date, Unigen™ has yielded multiple novel immuno-oncology drug targets, potential first or best-in-class clinical stage immuno-oncology programs, validating partnerships with multiple pharmaceutical companies, and undisclosed programs in its early-stage pipeline.
Funding history · 14 rounds · $40.3M total
2023-01
Follow-on PO
Undisclosed
2020-03
Follow-on PO
Undisclosed
2018-06
Follow-on PO
Undisclosed
2016-10
Follow-on PO
Undisclosed
2014-09
Follow-on PO
Undisclosed
2014-02
Follow-on PO
Undisclosed
2013-01
Follow-on PO
Undisclosed
2011-09
Follow-on PO
Undisclosed
2011-01
Follow-on PO
Undisclosed
2009-10
Follow-on PO
Undisclosed
2007-06
PIPE
$4.9M
★ GlobalServe
2002-01
Follow-on PO
Undisclosed
2000-08
Follow-on PO
Undisclosed
2000-07
B Round
$35.4M
★ Apax★ Yozma Group Korea★ Giza Venture Capital★ 3 additional investors★ Pequot Capital Management
Headcount over time
From 90 (2019-03) to 110 (2026-03) · +20 (+22%) · 18 points · source: Finder history + radar grounding
Q&A
- What is Compugen's primary focus?
- Compugen is a clinical-stage cancer immunotherapy company that uses an AI-powered predictive computational discovery platform to identify novel drug targets and develop cancer immunotherapies.
- When did Compugen go public on NASDAQ?
- Compugen went public on NASDAQ in August 2000.
- How many employees does Compugen currently have?
- Compugen has 51-200 employees.
- What was the amount raised in Compugen's Public Offering in January 2023?
- In January 2023, Compugen raised $50,000,000 through a Public Offering.
- What was a significant recent development for Compugen regarding a milestone payment?
- In May 2024, Compugen was set to receive a milestone payment triggered by the dosing of the first patient in the second Phase 3 trial evaluating Rilvegostomig.
- What was a key partnership announcement for Compugen in December 2023?
- In December 2023, Gilead and Compugen announced an exclusive license agreement for a novel pre-clinical immunotherapy program.
- What was a recent intellectual property expansion for Compugen?
- In November 2024, Compugen expanded its intellectual property portfolio with a new U.S. patent covering the triple combination use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG antibodies.
- What was a recent clinical trial update for Compugen's COM701 program?
- In July 2025, Compugen announced the first patient was dosed in the COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer.
- What was a significant financial transaction for Compugen in December 2025?
- In December 2025, Compugen monetized a portion of its Rilvegostomig future royalties to AstraZeneca for up to $90 million.
Team · 8
Eli Mintz
Founder · Founder
Simchon Faigler
Founder · Founder
Amir Natan
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentDrug Delivery
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business model
B2B
Highlights
1 Patents
Tags
immunologyoncologybiotechnologybioinformaticsantibodiesdrug-discoveryproteinspharmaceuticalsimmunotherapycancer-therapyautoimmune-diseasespatientspharma-companiescancer
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | cgen.com/overview/default.aspx |
|---|---|
| linkedin.com/company/753626 | |
| YouTube | youtube.com/channel/UCr8jYQMyiCsFWKfDQAevd6A/featured |
| Crunchbase | crunchbase.com/organization/compugen |
Identifiers & details
| Legal name | Compugen Ltd. |
|---|---|
| Founded | 1993 |
| Employees (exact) | 110 |
| Offices | South San Francisco |
| Market cap | $143.2M |
| Status reason | Public on NASDAQ on Aug, 2000;Public on TASE on Jan, 2002; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2000-08 | NASDAQ | CGEN | |
| Listing | 2002-01 | TASE | CGEN |
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 511779639 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 1993-02-10 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 1998 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | הרוקמים 26 חולון |